Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Thomas M. who wrote (679)	7/23/1998 2:22:00 PM
From: Rocketman	Respond to of 3202

Interesting report, thanks! It doesn't mention a thing about Synteni in it though, or how the Monsanto or Novartis deals will impact the revenue/profit streams. Seems to have too narrow a view of INCY IMHO. Rman

To: Thomas M. who wrote (679)	7/29/1998 2:45:00 PM
From: Richard Huth	Respond to of 3202

Thank you for the report. Think the same as rocketman. Guess, after talking to Incyte 3 weeks ago that this year's earnings won't show much surprises (even with deals such as Novartis), but increasing chip-production could bring down costs a little bit, so for next year there might be room for some positive surprises. Incyte, even without much perspective in the next few month, is a good boat for longterm investors in rough waters likely to come. Because one thing is (my opinion) for sure, revenues and earnings will constantly go up for the next 8-12 quarters (even if slowly :-) ). Richard